Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Italy-based biopharmaceutical company Gentium and Israel-based Medison Pharma have entered into a 10 year defibrotide exclusive license and distribution agreement in Israel and the Palestinian Authority.
Subscribe to our email newsletter
Defibrotide is an investigational drug indicated to treat and prevent veno-occlusive disease (VOD).
As part of the agreement, Medison will manage the named-patient sales program, local registration, authorization, marketing, reimbursement, and medical affairs in these territories.
Defibrotide has been granted orphan drug status by the US Food and Drug Administration (FDA) and orphan medicinal product designation by the European Commission both to treat and to prevent VOD and fast track designation by the FDA to treat VOD.
Gentium’s marketing authorization application for defibrotide was recently accepted by the European Medicines Agency and was granted an accelerated assessment.
The company expects to file a new drug application with the FDA by the end of Q2 2011.
Following approval to market defibrotide, if any, Medison will have the exclusive right to promote, purchase, market and sell defibrotide in these territories.